Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals Inc. is a biotechnology company based in New York City, employing 185 people and generating $16 million in annual revenue. Synergy Pharmaceuticals focuses on developing innovative treatments for gastrointestinal (GI) disorders. Their research centers on uroguanylin analogs, a naturally occurring human GI peptide, to create therapies for chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). The company emphasizes scientifically driven innovation, aiming to provide treatments that enhance efficacy, safety, and tolerability while improving the patient experience. Synergy Pharmaceuticals is committed to offering novel treatment options for patients and healthcare providers, fostering rewarding opportunities for its employees, and creating exceptional value for its customers. Interested parties can visit Synergy Pharmaceuticals' website at http://www.synergypharma.com/about-us or follow them on Twitter at @SynergyPharma.